Soligenix
Update in progressSNGX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Soligenix, Inc. is a late‑stage biopharmaceutical company focused on rare diseases in the United States. It has two segments: Specialized BioTherapeutics and Public Health Solutions. The former includes SGX301 (HyBryte) for cutaneous T‑cell lymphoma in Phase 3 and several innate defense regulator programs (SGX942, SGX945, SGX302) at various trial stages. The latter pursues RiVax and other vaccine/therapeutic programs, many in preclinical or early trials.
Company score
- Sentiment
- 0.35
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.29
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Christopher J. Schaber Ph.D.
- Founded1987
- Employees13
- Websitewww.soligenix.com
Identifiers
- ISINUS8342233074
- FIGIBBG000FVMHG5
- LEI549300MN2EF9LQHLT817
- CUSIP258094101
- CIK0000812796